You are not logged in
Visit our Twitter
Visit our LinkedIn
New oral endocrine therapy options in breast cancer - PRE-SURVEY
If you wish to view the details for the meeting, then please click the button.
Back to the Meeting Details
For ER+/HER2- metastatic breast cancer, treatment with an oral SERD, like elacestrant, is more likely to benefit a patient with which of the following mutations?
All of the above
None of the above
Which would be your 2nd line treatment of choice for a CDK4/6i pretreated patient with an ESR1 mutated, PIK3CA WT, ER+/HER2- metastatic breast cancer?
Exemestane + everolimus
What percentage of patients with metastatic breast cancer have an ESR1 mutation after treatment with an aromatase inhibitor?
On a scale of 1 to 5, how do you rate your knowledge (with 5 as extremely knowledgeable) on clinical data of SERDs & their place in the treatment landscape?
On a scale of 1 to 5, how familiar are you (with 5 as extremely familiar) in optimization of treatment selection & sequencing decisions in ER+/HER2- advanced or metastatic breast cancer?
On a scale of 1 to 5, how confident (with 5 as extremely confident) are you in understanding the need & role of testing in ER+/HER2- advanced or metastatic breast cancer?
On average how many patients with advanced or metastatic breast cancer do you see each month?
Do you have any questions you would like to ask the faculty?
Submit Pre-Meeting Survey
COR2ED develops and implements high quality Independent Medical Education programmes to help improve the health of patients globally.
Disclaimer: The material and content contained in the website engage.cor2ed.com is for healthcare professionals only. Although every effort is made to ensure that the material within this website is accurate and timely, it is provided for informational and educational purposes only. The information provided is not intended as a substitute for medical professional help, advice, diagnosis or treatment and may not be applicable to every case or country.
© Copyright 2021 | All Rights Reserved